trastuzumab-deruxtecan Enhertu
Selected indexed studies
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. (N Engl J Med, 2022) [PMID:35665782]
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. (N Engl J Med, 2024) [PMID:39282896]
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. (J Clin Oncol, 2024) [PMID:37870536]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. (2022) pubmed
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. (2024) pubmed
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. (2024) pubmed
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. (2022) pubmed
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. (2023) pubmed
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. (2025) pubmed
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. (2026) pubmed
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. (2020) pubmed
- Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. (2022) pubmed
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. (2020) pubmed